Loading
A phase 1/2 trial of Precemtabart tocentecan in non-small-cell lung cancer and small-cell lung cancer, run by EMD Serono Research & Development Institute, Inc., active and no longer recruiting.
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) is a phase 1/2 interventional study registered as NCT06710132 by EMD Serono Research & Development Institute, Inc., with 184 participants enrolled, started 2025-01-29 and due to reach its primary completion in 2027-12-23. Interventions recorded: M9140. Conditions listed: Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Merck KGaA (EMD Serono), Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/